StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck noxafil (posaconazole, legacy) — U.S. reported growth YoY (%) (%)

Form 8-K Table 3a / 3b Product Sales

QuarterlyAnnual
Latest, Q4 2024
-149.0%
Period ended Dec 31, 2024
Change on a year earlier
-77.0 pts
-72.0% in Q4 2023
History
23 quarters
Since Q4 2017
Sources
23
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNoxafil (posaconazole, legacy) — U.S. reported growth YoY (%) (%)Year on yearSource
Q4 2024Dec 31, 2024-149.0%-77.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024-85.0%-14.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2024Mar 31, 2024-43.0%–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-72.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 2023-71.0%-41.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 2023-32.0%-43.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q3 2022Sep 30, 2022-30.0%-74.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202211.0%–Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-35.0%-131.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-25.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 202144.0%+127.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q1 2021Mar 31, 202196.0%+188.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 2020-83.0%–Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-94.0%-109.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020-92.0%-104.0 ptsForm 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 2019-85.0%-93.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗

Cite this data

StockData. (2026). Merck Noxafil (posaconazole, legacy) — U.S. reported growth YoY (%) (%), quarterly Q4 2017–Q4 2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_noxafil_us_nom_yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.